Milestone Pharmaceuticals
Investment
area
Novo Ventures
Novo Ventures
Region
Eastern USA
Eastern USA
Date of
investment
June 2017
June 2017
Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals
Investment
area
Novo Ventures
Novo Ventures
Region
Eastern USA
Eastern USA
Date of
investment
June 2017
June 2017
Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals
Investment
area
Novo Ventures
Novo Ventures
Region
Eastern USA
Eastern USA
Date of
investment
June 2017
June 2017
Website
Visit their website
Visit their website
Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.